All In Biotech

Drug Trial Radar · NCT02608268

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

252

Actual

Start

Nov 23, 2015

Primary completion

Aug 30, 2022

Study completion Aug 30, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors

Conditions

  • Advanced Malignancies

Interventions

  • MBG453Drug

    Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

  • PDR001Drug

    Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

  • DecitabineDrug

    commercially available chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I-Ib and Dose Ranging Part: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment PeriodTime frame: From first dose of study medication up to 30 days after last dose, with a maximum duration of 2 years for sabatolimab and 5 years for sabatolimab in combination with spartalizumab
  2. Phase I-Ib: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 28 days (sabatolimab single agent) and 56 days (sabatolimab+spartalizumab)
  3. Phase I-Ib and Dose Ranging Part: Number of Participants With Dose Reductions and Dose Interruptions of SabatolimabTime frame: From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab
  4. Phase Ib: Number of Participants With Dose Reductions and Dose Interruptions of SpartalizumabTime frame: From first dose of study medication up to last dose, with a maximum duration of 4.9 years
  5. Phase I-Ib and Dose Ranging Part: Dose Intensity of SabatolimabTime frame: From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab
  6. Phase Ib: Dose Intensity of SpartalizumabTime frame: From first dose of study medication up to last dose, with a maximum duration of 4.9 years
  7. Phase II: Overall Response Rate (ORR) Per RECIST v1.1Time frame: From start of treatment until end of treatment, assessed up to 2.9 years

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • Sidney Kimmel CCC At JH Sidney Kimmel CCC

    Baltimore, Maryland

  • Dana Farber Cancer Institute DFCI - Brookline

    Boston, Massachusetts

  • UT M.D Anderson Cancer Center

    Houston, Texas

  • Mays Cancer Ctr Uthsa Mdacc

    San Antonio, Texas

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Leiden, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Geneva, Switzerland

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.